Assuming costs is required, the following results were found.

  • Tecfidera (dimethyl fumarate)

    in clinical studies. However, in one analysis, they were compared indirectly and were found to have similar benefits. Costs Tecfidera and Aubagio are only available as brand-name drugs. Generic versions of these drugs aren't available. Generic forms are...

    https://mschristian.org/index.php/articles/2-uncategorised/8434-tecfidera-dimethyl-fumarate
  • Economic Factors Amplify Burden of Disease for Patients With Multiple Sclerosis

    the future." Economic factors may include loss of income for the patient, care-giving time for the family, and societal costs, which include burden on the healthcare system due to high healthcare utilization. Not surprisingly, the evidence shows that...

    https://mschristian.org/index.php/blog/economic-factors-amplify-burden-of-disease-for-patients-with-multiple-sclerosis
  • Tecfidera (dimethyl fumarate)

    in clinical studies. However, in one analysis, they were compared indirectly and were found to have similar benefits. Costs Tecfidera and Aubagio are only available as brand-name drugs. Generic versions of these drugs aren't available. Generic forms are...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • High cost of MS medicines forcing patients to take 'drastic actions' - STAT

    medicine than prescribed, according to the survey by the National Multiple Sclerosis Society. Meanwhile, the out-of-pocket costs associated with the medicines meant that 25% of the nearly 600 patients who responded to the survey spent less on...

    https://mschristian.org/index.php/blog/high-cost-of-ms-medicines-forcing-patients-to-take-drastic-actions-stat
  • Learning about FSA and HSA Cards for healthcare savings

    a flexible spending arrangement by the IRS) are both tax-advantaged accounts that allow you to save specifically for medical costs. What is the difference between an FSA and HSA account? The most significant difference between flexible spending accounts...

    https://mschristian.org/index.php/blog/learning-about-fsa-and-hsa-cards-for-healthcare-savings
  • Pharmacy Benefit Managers and Their Role in Drug Spending - Are they the Good Guys or Bad Guys

    April 2019 Pharmacy benefit manager have a significant behind-the-scenes impact in determining drug costs and patients’ access to medications. Some experts think pharmacy benefit managers need to move their business model away from securing rebates...

    https://mschristian.org/index.php/blog/pharmacy-benefit-managers-and-their-role-in-drug-spending-are-they-the-good-guys-or-bad-guys
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    of 2019 as compared to $43.4 million for the same period in 2018. The increase in the third quarter of 2019 was due to costs associated with the Company’s continuing expansion of research and development activities, including: -- Clinical study,...

    https://mschristian.org/index.php/blog/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    of 2019 as compared to $43.4 million for the same period in 2018. The increase in the third quarter of 2019 was due to costs associated with the Company’s continuing expansion of research and development activities, including: -- Clinical study,...

    https://mschristian.org/index.php/articles/2-uncategorised/9192-atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Pharmacy Benefit Managers and Their Role in Drug Spending - Are they the Good Guys or Bad Guys

    April 2019 Pharmacy benefit manager have a significant behind-the-scenes impact in determining drug costs and patients’ access to medications. Some experts think pharmacy benefit managers need to move their business model away from securing rebates...

    https://mschristian.org/index.php/articles/2-uncategorised/8865-pharmacy-benefit-managers-and-their-role-in-drug-spending-are-they-the-good-guys-or-bad-guys
  • Readers React: We need to lower prescription drug costs - Morning Call

    React: We need to lower prescription drug costs Morning Call Original link Readers React: We need to lower prescription drug costs Morning Call Original link

    https://mschristian.org/index.php/blog/readers-react-we-need-to-lower-prescription-drug-costs-morning-call
  • Economic Factors Amplify Burden of Disease for Patients With Multiple Sclerosis

    the future." Economic factors may include loss of income for the patient, care-giving time for the family, and societal costs, which include burden on the healthcare system due to high healthcare utilization. Not surprisingly, the evidence shows that...

    https://mschristian.org/index.php/articles/2-uncategorised/8610-economic-factors-amplify-burden-of-disease-for-patients-with-multiple-sclerosis
  • Aubagio (teriflunomide)

    there were only 50 people in the study, more research is needed to make a definitive comparison between the two drugs. Costs Aubagio and Tecfidera are both brand-name drugs. They don't have generic forms. Brand-name medications usually cost more than...

    https://mschristian.org/index.php/articles/2-uncategorised/8433-aubagio-teriflunomide
  • Industry executives: Profits drive rising prices for MS drugs

    the price increases are purely what can maximize profit," one executive said. "There's no other rationale for it, because costs [of producing the drug] have not gone up by 10% or 15%; you know, the costs have probably gone down." The executives...

    https://mschristian.org/index.php/blog/industry-executives-profits-drive-rising-prices-for-ms-drugs
  • Aubagio (teriflunomide)

    there were only 50 people in the study, more research is needed to make a definitive comparison between the two drugs. Costs Aubagio and Tecfidera are both brand-name drugs. They don't have generic forms. Brand-name medications usually cost more than...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • High cost of MS medicines forcing patients to take 'drastic actions' - STAT

    medicine than prescribed, according to the survey by the National Multiple Sclerosis Society. Meanwhile, the out-of-pocket costs associated with the medicines meant that 25% of the nearly 600 patients who responded to the survey spent less on...

    https://mschristian.org/index.php/articles/2-uncategorised/9868-high-cost-of-ms-medicines-forcing-patients-to-take-drastic-actions-stat
  • Learning about FSA and HSA Cards for healthcare savings

    a flexible spending arrangement by the IRS) are both tax-advantaged accounts that allow you to save specifically for medical costs. What is the difference between an FSA and HSA account? The most significant difference between flexible spending accounts...

    https://mschristian.org/index.php/articles/2-uncategorised/9762-learning-about-fsa-and-hsa-cards-for-healthcare-savings
  • CareCentrix Releases New Series of #CareTalk Podcasts and Videos Shot Live at HLTH - P&T Community

    spoke about the stigma and lack of attention around mental health in the U.S., as well ashow reducing the ancillary costs associated with mental illness lowers the overall costs for a healthcare system. Dr. Scott Shreeve, Founder and CEO of Crossover...

    https://mschristian.org/index.php/articles/2-uncategorised/9188-carecentrix-releases-new-series-of-caretalk-podcasts-and-videos-shot-live-at-hlth-p-t-community
  • #ECTRIMS2019 - Are Injectables Inappropriate for Active Relapsing MS? - Multiple Sclerosis News Today

    in Europe, which included 16,808 patients, approximately half of whom had relapsing-remitting MS (RRMS). Results showed that costs and utility (meaning the patient’squality of life) were highly correlated with disease severity and progression. In fact,...

    https://mschristian.org/index.php/articles/2-uncategorised/8956-ectrims2019-are-injectables-inappropriate-for-active-relapsing-ms-multiple-sclerosis-news-today
  • Worldwide Genomics Markets, 2020-2027 - Comprehensive Analysis on the $31.1 Billion-Projected Industry - P&T Community

    the genomic sequence. Earlier procured only by doctors, these tests can now be taken by anyone curious about their DNA and costs approximately USD 1,000. The company has also begun the commercialization of this technique for newborn's genomic sequencing...

    https://mschristian.org/index.php/blog/worldwide-genomics-markets-2020-2027-comprehensive-analysis-on-the-31-1-billion-projected-industry-p-t-community
  • CareCentrix Releases New Series of #CareTalk Podcasts and Videos Shot Live at HLTH - P&T Community

    spoke about the stigma and lack of attention around mental health in the U.S., as well as how reducing the ancillary costs associated with mental illness lowers the overall costs for a healthcare system. Dr. Scott Shreeve, Founder and CEO of Crossover...

    https://mschristian.org/index.php/blog/carecentrix-releases-new-series-of-caretalk-podcasts-and-videos-shot-live-at-hlth-p-t-community

Results 1 - 20 of 51